title: Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice.
abstract: BACKGROUND
  Peginterferon-alpha-based therapy frequently leads to neutropenia. It remains unclear whether neutropenia is associated with bacterial infection in chronic hepatitis C (CHC).
  
  
  OBJECTIVE
  To evaluate the risk of bacterial infection and neutropenia in patients with CHC treated with peginterferon-alpha/ribavirin.
  
  
  METHODS
  In all, 207 patients with CHC with (group A, n = 30) and without (group B, n = 177) baseline neutropenia were treated with peginterferon-alpha/ribavirin.
  
  
  RESULTS
  Group A had significantly higher rates of moderate (<750 cells/microL) and severe (<500 cells/microL) neutropenia than group B (70.0% and 26.7% vs. 20.3% and 8.5% respectively, both P < 0.0001). The sustained virological response rate was similar between patients with and without neutropenia, at baseline or during treatment. Bacterial infection occurred in 4.3% of patients. Group A and patients with lower baseline neutrophil counts had substantially higher rates of bacterial infection. Patients with cirrhosis had significantly higher rates of infection during combination therapy than those without cirrhosis (15%, 3 of 20 vs. 3.2%, 6 of 187, P = 0.045). Nadir neutrophil counts were not correlated to infection episodes.
  
  
  CONCLUSIONS
  Bacterial infection during peginterferon-based therapy for CHC was associated with comorbidity of cirrhosis, but not with neutropenia, whether at baseline or during treatment. Neutropenic CHC patients might be treated safely with close monitoring.
authors.affiliation: Department of Preventive Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
authors.forename: J-F
authors.initials: JF
authors.lastname: Yang
authors.forename: M-Y
authors.initials: MY
authors.lastname: Hsieh
authors.forename: N-J
authors.initials: NJ
authors.lastname: Hou
authors.forename: C-Y
authors.initials: CY
authors.lastname: Dai
authors.forename: J-F
authors.initials: JF
authors.lastname: Huang
authors.forename: Z-Y
authors.initials: ZY
authors.lastname: Lin
authors.forename: S-C
authors.initials: SC
authors.lastname: Chen
authors.forename: M-Y
authors.initials: MY
authors.lastname: Hsieh
authors.forename: L-Y
authors.initials: LY
authors.lastname: Wang
authors.forename: W-L
authors.initials: WL
authors.lastname: Chuang
authors.forename: M-L
authors.initials: ML
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000494:pharmacology*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a